We are live on !
Find out more
Oak Associates Portfolio holdings
AUM
$1.79B
Turnover
11.49%
1-Year Est. Return
51.38%
This Fund
S&P 500
This Quarter Est. Return
+33.49%
1 Year Est. Return
+51.38%
3 Year Est. Return
+152.22%
5 Year Est. Return
+176.54%
10 Year Est. Return
+769.34%
AUM
$1.79B
AUM Growth
+$301M
(+20%)
Cap. Flow
-$30.5M
Cap. Flow % of AUM
Cap. Flow %
-1.7%
Top 10 Holdings %
Top 10 Hldgs %
49.37%
Holding
148
New
8
Increased
9
Reduced
41
Closed
9
Avg Time Held
5.6
years
Top 10 Avg Time Held
5.7
years
Top 20 Avg Time Held
6.6
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ASML
ASML
|
+$17M |
| 2 |
Devon Energy
DVN
|
+$2.11M |
| 3 |
Amphenol
APH
|
+$969K |
| 4 |
Commault Systems
CVLT
|
+$500K |
| 5 |
NXP Semiconductors
NXPI
|
+$443K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Accenture
ACN
|
+$9.9M |
| 2 |
Broadcom
AVGO
|
+$8.95M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$5.84M |
| 4 |
KLA
KLAC
|
+$4.15M |
| 5 |
NetApp
NTAP
|
+$3.42M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 50.96% |
| 2 | Communication Services | 13.11% |
| 3 | Financials | 11.49% |
| 4 | Healthcare | 10.75% |
| 5 | Consumer Discretionary | 8.92% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
Newmont
NEM
$115B
| $2.59M | 0.14% |
27,679
| – | – |
2025 Q2
4 quarters
|
|
77
National Healthcare
NHC
$3.7B
| $2.48M | 0.14% |
11,724
| – | – |
2025 Q1
5 quarters
|
|
78
ESAB
ESAB
$4.16B
| $2.39M | 0.13% |
24,196
| – | – |
2023 Q1
13 quarters
|
|
79
Vertex Pharmaceuticals
VRTX
$133B
| $2.32M | 0.13% |
4,677
| – | – |
2020 Q2
24 quarters
|
|
80
Medpace
MEDP
$18.7B
| $2.32M | 0.13% |
4,383
| – | – |
2025 Q1
5 quarters
|
|
81
Merck
MRK
$358B
| $2.16M | 0.12% |
16,835
| – | – |
2019 Q1
29 quarters
|
|
82
Incyte
INCY
$23.5B
| $2.11M | 0.12% |
18,643
| – | – |
2024 Q1
9 quarters
|
|
83
Mercado Libre
MELI
$91.8B
| $2.04M | 0.11% |
1,200
| – | – |
2024 Q2
8 quarters
|
|
84
iShares MSCI ACWI ex US ETF
ACWX
$17.4B
| $1.65M | 0.09% |
21,658
| – | – |
2025 Q4
2 quarters
|
|
85
Applovin
APP
$87.1B
| $1.55M | 0.09% |
3,000
| – | – |
2025 Q2
4 quarters
|
|
86
Eli Lilly
LLY
$1.14T
| $1.4M | 0.08% |
1,170
| – | – |
2025 Q3
3 quarters
|
|
87
Pegasystems
PEGA
$5.96B
| $1.37M | 0.08% |
45,725
+3,247
| +8% | +$116K |
2026 Q1
1 quarter
|
|
88
Stryker
SYK
$118B
| $1.33M | 0.07% |
4,221
| – | – |
2013 Q2
52 quarters
|
|
89
Veeva Systems
VEEV
$52.3B
| $1.29M | 0.07% |
7,296
-3,625
| -33% | -$598K |
2023 Q4
10 quarters
|
|
90
Zscaler
ZS
$41.6B
| $1.23M | 0.07% |
8,716
| – | – |
2023 Q4
10 quarters
|
|
91
Medtronic
MDT
$122B
| $1.21M | 0.07% |
15,485
| – | – |
2013 Q2
52 quarters
|
|
92
US Bancorp
USB
$92.8B
| $1.21M | 0.07% |
20,000
| – | – |
2025 Q2
4 quarters
|
|
93
Nutanix
NTNX
$19.1B
| $1.13M | 0.06% |
22,162
| – | – |
2026 Q1
1 quarter
|
|
94
Novo Nordisk
NVO
$172B
| $1.13M | 0.06% |
23,467
+1,825
| +8% | +$78.4K |
2025 Q3
3 quarters
|
|
95
Paylocity
PCTY
$9.24B
| $933K | 0.05% |
8,930
| – | – |
2018 Q3
31 quarters
|
|
96
V2X
VVX
$2.32B
| $891K | 0.05% |
11,952
| – | – |
2021 Q4
18 quarters
|
|
97
CNO Financial Group
CNO
$4.96B
| $822K | 0.05% |
16,126
| – | – |
2013 Q2
52 quarters
|
|
98
Elevance Health
ELV
$95.4B
| $794K | 0.04% |
2,054
| – | – |
2013 Q2
52 quarters
|
|
99
Adeia
ADEA
$2.34B
| $774K | 0.04% |
23,504
| – | – |
2026 Q1
1 quarter
|
|
100
PTC
PTC
$21.1B
| $726K | 0.04% |
6,386
| – | – |
2026 Q1
1 quarter
|
|
Similar funds
Oak Associates's Q2 2026 Portfolio in Review
As of Q2 2026, Oak Associates held 148 positions worth $1.79B, up 20% from $1.49B the previous quarter. Its ten largest holdings account for 49% of the portfolio.
Oak Associates's Q2 2026 filing shows 8 new, 9 increased, 41 reduced and 9 closed positions. Its largest new stake was ASML: 10,698 shares worth $21.3M. The largest sale was Accenture, an estimated $9.9M.
By sector, the portfolio is most concentrated in Technology at 51% of assets, up from 44% a quarter earlier, followed by Communication Services and Financials.
- Oak Associates's largest Q2 2026 buy was ASML: 10,698 shares worth $21.3M.
- Oak Associates added most to Devon Energy in Q2 2026, an estimated $2.11M increase.
- Oak Associates's biggest Q2 2026 reduction was Broadcom, cutting an estimated $8.95M.
- Oak Associates fully exited Accenture in Q2 2026, selling an estimated $9.9M.
- Oak Associates's ten largest holdings make up 49% of its $1.79B portfolio in Q2 2026.
- Oak Associates opened 8 new positions and closed 9 in Q2 2026.
- Oak Associates's portfolio value rose 20% quarter-over-quarter to $1.79B.
Based on Oak Associates's 13F filing for Q2 2026, filed 14 Aug 2026.